KS

Kamal Singh Sodhi

Director Director DIN 03643669
DIN 03643669 First appointment Oct 2011 Primary industry Life Sciences
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Oct 2011
Shareholding value β€’β€’β€’β€’ Premium profile

About Kamal Singh Sodhi

Data last updated:

Kamal Singh Sodhi was a Director at Igenerix Pharma Private Limited (2011) and Director at Hampton Pharma Private Limited (2011). The companies operate in Life Sciences and Pharma.

DIN 03643669
Primary Designation Director
Industry Life Sciences
First Appointment 12 Oct 2011

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Igenerix Pharma Private Limited U73200UP2008PTC170816
Director12 Oct 20112008₹4.42 Cr (FY 2021)Active
Hampton Pharma Private Limited U73200UP2008PTC170814
Director12 Oct 20112008₹1.90 Cr (FY 2017)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Igenerix Pharma Private Limited
Hampton Pharma Private Limited
Premium access

Shareholding and investment profile for Kamal Singh Sodhi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kamal Singh Sodhi

Kamal Singh Sodhi was first appointed on 12 Oct 2011 as Director at Igenerix Pharma Private Limited.

Kamal Singh Sodhi held 2 earlier board appointments: Igenerix Pharma Private Limited (Director, 12 Oct 2011 to 04 Nov 2011); Hampton Pharma Private Limited (Director, 12 Oct 2011 to 04 Nov 2011).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available